These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 9332322)

  • 41. The use of low dose Orgaran in heparin-induced thrombocytopenia associated with in vitro platelet aggregation at higher Orgaran concentrations.
    Hill GR; Hickton C; Henderson S; Patton WN
    Clin Lab Haematol; 1997 Jun; 19(2):155-7. PubMed ID: 9218159
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Value of orgaran in hemodialysis during heparin-induced thrombopenia].
    Lamriben L; Tiberghien F; Delacour JL; Floriot C; Wagschal G; Daoudal P; Ory JP
    Presse Med; 1996 Sep; 25(28):1303. PubMed ID: 8949796
    [No Abstract]   [Full Text] [Related]  

  • 43. [Thrombosis of a cardiopulmonary bypass circuit despite recommended hypocoagulation with danaparoid during the acute phase of type II heparin-induced thrombocytopenia].
    Salmi L; Elalamy I; Leroy-Matheron C; Houel R; Thébert D; Duvaldestin P
    Ann Fr Anesth Reanim; 2006; 25(11-12):1144-8. PubMed ID: 17174213
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of heparin-induced thrombocytopenia.
    Peters FP
    J Thorac Cardiovasc Surg; 1997 Sep; 114(3):517-8. PubMed ID: 9305220
    [No Abstract]   [Full Text] [Related]  

  • 45. [Danaparoid sodium for dialysis in heparin-associated thrombocytopenia].
    Ben Ami R; Rachmimov R; Berliner S
    Harefuah; 1999 Mar; 136(5):361-4, 419. PubMed ID: 10914239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ardeparin and danaparoid.
    Dimens Crit Care Nurs; 2000; 19(4):13-4. PubMed ID: 11998151
    [No Abstract]   [Full Text] [Related]  

  • 47. Preventing complications in heparin-induced thrombocytopenia. Alternative anticoagulants are improving patient outcomes.
    Rice L; Nguyen PH; Vann AR
    Postgrad Med; 2002 Sep; 112(3):85-9. PubMed ID: 12360660
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaparoid.
    Neuhaus TJ; Goetschel P; Schmugge M; Leumann E
    Pediatr Nephrol; 2000 Aug; 14(8-9):713-6. PubMed ID: 10955913
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drugs for the prevention and treatment of thrombosis in patients with heparin-induced thrombocytopenia.
    Lubenow N; Greinacher A
    Am J Cardiovasc Drugs; 2001; 1(6):429-43. PubMed ID: 14728002
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Persistent heparin-induced thrombocytopenia: danaparoid cross-reactivity or delayed-onset heparin-induced thrombocytopenia? A case report.
    Horlait G; Minet V; Mullier F; Michaux I
    Blood Coagul Fibrinolysis; 2017 Mar; 28(2):193-197. PubMed ID: 27100305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
    Tardy-Poncet B; Tardy B; Reynaud J; Mahul P; Mismetti P; Mazet E; Guyotat D
    Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II.
    Zöhrer' B; Zenz W; Rettenbacher A; Covi P; Kurnik K; Kroll H; Grubbauer HM; Muntean W
    Acta Paediatr; 2001 Jul; 90(7):765-71. PubMed ID: 11519979
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Orgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia: role of adjunctive plasmapheresis.
    Schmahl KS; Ganjoo AK; Harloff MG
    J Cardiothorac Vasc Anesth; 1997 Apr; 11(2):262-3. PubMed ID: 9106004
    [No Abstract]   [Full Text] [Related]  

  • 54. Thromboembolic complications in a patient with heparin-induced thrombocytopenia (HIT) showing cross-reactivity to a low molecular weight heparin-treatment with Org 10172 (Lomoparan).
    Muhm M; Claeys L; Huk I; Koppensteiner R; Kyrle PA; Minar E; Stümpflen A; Ehringer H; Polterauer P
    Wien Klin Wochenschr; 1997 Feb; 109(4):128-31. PubMed ID: 9076930
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Heparin induced thrombocytopenia. Experiences in 12 heart surgery patients.
    Sodian R; Loebe M; Gorman KF; Riess H; Hetzer R
    ASAIO J; 1997; 43(5):M430-3. PubMed ID: 9360077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIT/HITT and alternative anticoagulation: current concepts.
    Lakshmanan S; Saha B; Rittoo D
    Br J Anaesth; 2003 Sep; 91(3):445; author reply 445-6. PubMed ID: 12966934
    [No Abstract]   [Full Text] [Related]  

  • 57. [Is it safe and cost effective... Danaparoid (Orgaran) as an anticoagulant for mechanical autotransfusion with Cell Saver 5 (Hemonetics),Anaesthesist (2001) 50:26-31].
    Lorentz A
    Anaesthesist; 2001 Oct; 50(10):792. PubMed ID: 11702330
    [No Abstract]   [Full Text] [Related]  

  • 58. Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass.
    von Segesser LK; Mueller X; Marty B; Horisberger J; Corno A
    Perfusion; 2001 Sep; 16(5):411-6. PubMed ID: 11565896
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
    Jeske WP; Walenga JM
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1171-80. PubMed ID: 12211410
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of heparin-induced thrombocytopenia during continuous renal replacement therapy.
    Davenport A
    Am J Kidney Dis; 1998 Oct; 32(4):E3. PubMed ID: 10074589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.